Adenovirus (AdV) infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). To evaluate the use of molecular AdV testing in HSCTat our institution and identify risk factors for AdV viremia and disease, we performed a retrospective cohort study of all HSCT recipients who had undergone AdV polymerase chain reaction testing over a 2-year period. Two cohorts were identified: cohort 1, comprising patients testing positive for AdV (n 5 7) and cohort 2, comprising patients testing negative (n 5 36). Overall patient characteristics were not statistically significantly different between the 2 cohorts. A comparison of cohort 1 and cohort 2 identified the following medication exposures as risk factors influencing AdV status: preparatory regimens using fludarabine (relative risk [RR], 8.73; 95% confidence interval [CI], 1.18-64.27; P 5 .006), melphalan (RR, 3.47; 95% CI, 0.76-15.94: P 5 .08), and/or cyclophosphamide (RR, 0.18; 95% CI, 0.02-1.4; P 5 .05), and GVHD prophylaxis with methylprednisone (RR, 3.73; 95% CI, 1.01-13.9; P 5 .04). AdV-positive patients had higher grades of GVHD and higher rates of GVHD of the gastrointestinal tract (RR, 4; 95% CI, 1.18-13.5; P 5 .03) compared with AdV-negative patients. Four of the 7 AdV-positive patients had concomitant clinical manifestations of disease, including pneumonia, diarrhea, and/or disseminated disease. Clinical outcomes in symptomatic patients included resolution of disease in 2 patients and death in 2 patients. All 7 AdV-positive patients received antiviral therapy, including 1 patient with severe disseminated disease that resolved after administration of liposomal cidofovir. Our study at a large pediatric HSCT center provides important preliminary data for the development of a prospective trial destined to identify specific HCST patient subpopulations that might benefit most from molecular screening and early preemptive therapy.
INTRODUCTION
Adenovirus (AdV) is an important cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT), particularly in pediatric patients [1, 2] . The reported incidence of AdV infection in HSCT recipients ranges from 5% to 47% [3, 4] , with 29% to 75% of infected patients manifesting disease symptoms that can be attributed to AdV infection [5, 6] . Previous studies in pediatric bone marrow transplantation recipients have shown AdV infection in 6% to 46% of patients [7, 8] . Up to 82% of those with AdV detected in peripheral blood samples do not survive [9] .
AdV polymerase chain reaction (PCR) can be used to detect viral DNA in whole blood, plasma, urine, stool, conjunctiva, and broncheoalveolar lavage specimens [3, [10] [11] [12] [13] . Adenoviral DNA has been detected in stool and urine preceding disseminated infection [10, 11] . DNA levels .1 Â 10 6 /g of stool have been associated with AdV viremia [3] . No correlation between a specific peripheral blood DNA copy number and clinical disease or mortality has been shown; however, rising viral peripheral blood DNA levels have been associated with increased mortality, suggesting that a threshold may exist [4, 14] .
Clinical manifestations of AdV in HSCT recipients include upper and lower respiratory tract diseases, hepatitis, genitourinary tract diseases, gastrointestinal (GI) diseases, central nervous system diseases, and disseminated diseases. Diarrhea is the most common presentation of AdV disease [1, 4] . Hemorrhagic cystitis and AdV DNA in stool have been shown to precede the onset of disseminated disease [4, 11] . Clinical diagnosis of AdV disease can be delayed because of the variable clinical presentations and the complicated clinical picture post-HSCT, including graft-versus-host disease (GVHD) [15] . However, PCR positivity in blood precedes clinical symptoms by a median of 3 weeks and presents a potential opportunity to intervene with the goal of improving outcomes [9, 15] .
Multiple groups have attempted to identify specific risk factors for infection and/or disease to identify populations at greatest risk for poor outcome [16, 17] . Published risk factors for AdV infection include younger age, GVHD, second HSCT, allogeneic transplantation, T cell depletion, unrelated or mismatched grafts, total body irradiation (TBI), lymphopenia, bone marrow as the stem cell source, and myelodysplastic syndrome as indications for transplantation [16, 18] . Known risk factors for disseminated disease include the number of sites of AdV detection, immunosuppressive therapy, lymphocytopenia, and detection of rising AdV viral load in blood [2, 4, 12] .
The currently available antiviral therapy for AdV infection is i.v. cidofovir, which has substantial toxicities, including nephrotoxicity, bone marrow suppression, and electrolyte disarray, limiting its clinical utility in asymptomatically infected patients [6, 19] . An algorithm for testing and treatment has been published for application to a pediatric HSCT population; however, the intervention studied was i.v. cidofovir [17] . Newer therapies with efficacy against AdV but lower toxicity, such as lipophilic cidofovir (CMX001), are in development and have been used anecdotally in the setting of AdV disease in HSCT recipients [2] . In addition, cytotoxic T lymphocyte infusion has shown effectiveness in treating patients with AdV disease [14, 20, 21] . A strategy incorporating the use of newer, less toxic therapies may allow treatment of a broader group of patients at risk for disease.
The availability of less toxic therapies, in conjunction with the increasingly widespread availability of PCR, has the potential to improve morbidity and mortality related to AdV disease in the HSCT population.
However, many areas of uncertainty remain, including the selection of specific patient subpopulations at greatest risk for severe disease, the potential safety and efficacy of prophylaxis, the role of prospective screening with potential preemptive therapy, and the determination of a viral load cutoff that is predictive of disease development.
In the present retrospective cohort study over a 2-year period at our institution, we identified risk factors predictive of AdV infection in pediatric HSCT recipients.
METHODS
Quantitative real-time AdV PCR testing was performed at Viracor-IBT Laboratories (Lee's Summit, MO). The assay was designed to detect all 52 serotypes of AdV and had a lower limit of detection of 100 AdV DNA copies/mL.
Between May 2008 and April 2010, 185 pediatric patients who had undergone quantitative AdV PCR testing were retrospectively identified from the Children's National Medical Center clinical microbiology laboratory database. Forty-eight of these 185 patients had undergone HSCT, 42 of whom had complete medical records available for review and were included in this study. AdV testing during this period was performed before the implementation of routine AdV PCR screening in this patient population. The vast majority of subjects (33 of 42; 79%) underwent testing based solely on clinical suspicion. Sources tested in symptomatic patients included blood, stool, urine, broncheoalveolar lavage, and/or sputum specimens, depending on clinical symptomatology. A much smaller subset of subjects (9 of 42; 21%) was tested as part of routine screening (of blood specimens) instituted at the discretion of specific attending physicians.
A data extraction tool was developed and applied systematically to assess all 42 patient records. Factors assessed included underlying diagnosis, type of stem cell transplantation (including HLA match and stem cell source), preparative regimen, GVHD prophylaxis, date of engraftment, surveillance for other viruses (ie, Epstein-Barr virus, cytomegalovirus, herpes simplex virus, varicella-zoster virus, BK virus, and human herpsesvirus-6), antiviral therapies used for prophylaxis or treatment, post-transplantation complications, and GVHD status (presence, type, and severity). Specific information on each patient's AdV status was documented as well, including the number of AdV PCRs performed, time from HSCT to the first positive PCR, duration of AdV positivity, peak viral load, absolute neutrophil count (ANC) and absolute lymphocyte count (ALC) at time of peak viral load, time to recovery of ALC .500, clinical presentation (when applicable), treatment course, and outcome.
This information was then entered into an electronic database for analysis.
Two patient cohorts were identified: cohort 1, comprising patients who tested positive for AdV (n 5 7) and cohort 2, comprising patients who tested negative (n 5 35). Clinical data were collected from all 42 patients and entered into the electronic database for analysis.
Patients testing positive for AdV (termed ''infection'') were further categorized into 2 groups: asymptomatic patients with no clinical evidence of disease and symptomatic patients (termed ''disease'') with clinical manifestations of infection, such as fever, diarrhea, respiratory symptoms, or disseminated disease.
Statistical analysis included unadjusted and adjusted logistic regression analysis to identify factors predicting AdV positivity. Unadjusted categorical variables including sex, underlying diseases, and type of stem cell transplantation were compared using the c 2 test. We also compared continuous variables, such as length of AdV positivity, using the nonparametric method. A separate risk analysis for subjects tested due to clinical symptoms (the vast majority) rather than routine screening was not possible, because of small sample size. A P value \ .05 was considered statistically significant.
RESULTS
Overall patient characteristics were not statistically different between the 2 cohorts (Table 1) . AdV infection was detected in 7 of 42 HSCT recipients (16.6%; 3 females and 4 males). The median age of AdV-infected patients at the time of HSCT was 7 years (range, 0-17 years). Underlying diagnoses included relapsed acute myelogenous leukemia, secondary myelodysplastic syndrome, b-thalassemia, congenital amegakaryocytic thrombocytopenia, severe aplastic anemia, and severe combined immunodeficiency disease.
The vast majority of the patients (33 of 42; 79%) received testing based only on clinical suspicion. In these patients, the most common symptom prompting testing was unexplained fever, and additional clinical symptoms prompting testing included rash, respiratory distress, GI symptoms, prolonged myelosuppression, hypotension, or sepsis syndrome. Thirty of the 33 patients (91%) tested in this manner were found to be AdV-negative, and 3 (9%) were AdV-positive. The clinical symptoms prompting testing in these 3 patients were diarrhea, fever with prolonged myelosuppression, and pneumonia.
A much smaller subset of patients (9 of 42; 21%) were tested as part of routine screening, instituted at the discretion of specific attending physicians. For these 9 patients, testing was initiated on posttransplantation day 0 to 112, the majority in the first 7 days after transplantation. Five of the 9 patients undergoing routine screening (56%) were AdV-negative, and the other 4 (44%) were AdV-positive. Although our sample size is small, the proportion of patients testing positive using this strategy was much higher than that testing positive based only on clinical suspicion (44% versus 9%).
Preparative regimens containing the following medications were identified as risk factors influencing AdV status (cohort 1 compared with cohort 2): fludarabine (relative risk [ Additional analysis of risk in the context of specific combination preparative regimens was attempted for the 13 different combinations of preparative regimens used in the patients included in this study. The largest number of patients received fludarabine/melphalan/ campath (cohort 1, n 5 11; cohort 2, n 5 4) and cyclophosphamide/TBI regimens (cohort 1, n 5 9; cohort 2, n 5 0). We did not detect a statistically significant difference with regard to receipt of either regimen and risk for AdV positivity (P 5 .18 for fludarabine/melphalan/campath; P 5 .13 for cyclophosphamide/TBI). For the other 11 combination regimens, there were not adequate numbers of patients to provide sufficient power for risk analysis between cohorts. GVHD prophylaxis with methylprednisone was associated with an increased risk of AdV infection (RR, 3.73; 95% CI, 1.01-13.9; P 5 .04). Other medications used for GVHD prophylaxis included cyclosporine (RR, 0.62; 95% CI, 0.11-3.42; P 5 .60), tacrolimus (RR, 1.18; 95% CI, 0.02-7.22; P 5 .85), mycophenolate mofetil (RR, 0.74; 95% CI, 0.10-5.2; P 5 .75), sirolimus (RR, 1.63; 95% CI, 0.29-9.0; P 5 .60), ATG (RR, 0.37; 95% CI, 0.05-2.78; P 5 .30), and methotrexate (RR, 0.78; 95% CI, 0.2-2.98; P 5 .71), none of which showed increased risk for development of AdV infection. Compared with AdV-negative patients, AdV-positive patients had significantly higher GVHD grades with higher rates of GVHD of the GI tract (RR, 4; 95% CI, 1.18-13.5; P 5 .03) (Figure 1) .
Other variables assessed that were not associated with a statistically significant increase in risk for AdV infection included stem cell source ( (Table 1) . However, 5 of the 7 patients who developed AdV infection had a nonmalignant disorder as the underlying diagnosis.
The concomitant use of antiviral therapies, such as acyclovir and ganciclovir, for herpes simplex virus and/or cytomegalovirus prophylaxis was not associated with altered risk of AdV positivity or disease (data not shown).
Four of the 7 AdV-positive patients (57%) had concomitant clinical manifestations of disease, including pneumonia, diarrhea, and/or disseminated disease. Clinical outcomes in the symptomatic patients included resolution of disease in 2 patients and death in 2 patients, with concomitant bacterial sepsis in 1 patient. Peak viral load was not predictive development of disease or severity (Table 3 ).
In the 7 AdV-positive patients, AdV was first detected between day 10 and day 1350 posttransplantation, with detection within the first 18 days posttransplantation in 6 of the 7 patients. The duration of documented AdV viremia in the AdV-positive patients ranged from 12 to 108 days.
The ALC coinciding with peak viral load in these patients ranged from 0-1130, with a mean of 310. Because the majority of patients developed AdV viremia in the first 18 days posttransplantation, we compared the minimum and maximum ALC in the first 18 days posttransplantation, as well as the mean number of days to recovery of ALC .500, between cohorts. Three of the 35 patients (9%) in the AdV-negative cohort and 1 of 7 (14%) in the AdV-positive cohort never achieved an ALC.500. In the remaining 38 patients, there was a non statistically significant trend toward shorter time to recovery of ALC for the AdVnegative cohort compared with the AdV-positive cohort (26.3 6 14.3 days versus 40.7 6 33.9 days; P 5 .08). There was no significant difference between cohorts in terms of minimum or maximum ALC in the first 18 days posttransplantation (mean minimum ALC, 17 6 15 for cohort 1 versus ALC, 14 6 13 for cohort 2 [P 5 .70]; mean peak ALC, 579 6 795 for cohort 1 versus ALC, 430 6 370 for cohort 2 [P 5 .60]).
DISCUSSION
This retrospective study at a large pediatric HSCT center confirms and expands on potential risk factors for AdV infection that have been identified in previous smaller studies in adults and mixed-age populations. Previously identified risk factors include age, T cell depletion, MUD stem cell source, HLA mismatch, presence of GVHD, immunosuppressive conditioning regimens, and use of steroids [3, 9, 12, 22] .
In this study, fludarabine and melphalan were associated with an increased risk of AdV viremia. Both of these drugs are known to result in slower lymphocyte recovery rates, leading to increased risk for viral infections. The increased risk of AdV infection in patients receiving these 2 drugs could also be associated with their use in combination with alemtuzumab, possibly acting as surrogates for alemtuzumab use. Although the use of alemtuzumab for T cell depletion has been associated with increased risk of AdV viremia in several other studies, the present study found no altered risk for patients who received this immunosuppressive agent or for those who received ATG.
GVHD prophylaxis with steroids was significantly associated with increased risk of AdV viremia in our patient population. This is likely secondary to the cell-mediated immunosuppressive nature of steroids, which is not characteristic of other GVHD prophylactic medications. Patients with GVHD of the GI tract also had an increased incidence of AdV infection. Given that the GI tract is a preferential target of AdV infection, damaged intestinal mucosa resulting from GVHD likely increases the infectivity of AdV, leading to more disseminated disease in these patients.
The present study did not find an increased risk of AdV infection associated with stem cell source (MRD or MUD), in disagreement with previous studies [4, 10, 17, 19] . It is important to note, however, that only 1 of our 7 AdV-positive patients received an MRD transplantation and had a fludarabinecontaining conditioning regimen. This might have affected our results, as might have our small sample size.
In our study population, 16% of the patients who underwent AdV PCR testing had detectable AdV viremia. This rate is consistent with previous studies in pediatric bone marrow transplantation recipients in which 6% to 46% of patients had detectable AdV [4, 23] . Of our patients with detectable AdV viremia, 57% had associated clinical symptoms, again consistent with previous studies in which 29% to 75% of patients with infection manifested disease that could be attributed to AdV [1, 4, 23] . It is often difficult to definitively attribute symptoms to a specific cause in these critically ill patients, given the high correlation among GVHD, AdV infection, and other transplantation-related illnesses. In the past, AdV was detected primarily by culture. As the use of molecular detection methods becomes more widely available, this wide variation in infection and disease rates may be retrospectively attributed to differences in sensitivity of detection techniques.
The most common clinical presentation of AdV disease reported in several studies is diarrhea [1, 3] . Only 2 of our 7 patients with detectable AdV had diarrhea, which resolved after treatment with cidofovir (i.v. and oral). Two of the patients in our population died, yielding an observed mortality rate of 40%. Both of these patients had respiratory symptoms as the primary manifestation of AdV disease and received appropriate antiviral therapy. This 40% mortality rate is consistent with previous studies in pediatric populations; however, no other study has reported an increased risk of death in the setting of respiratory illness. It is possible that AdV disease in the lung is more refractory to treatment.
We could not demonstrate any association between peak viral load and the likelihood of developing symptomatic disease and/or death. Although rising adenoviral titers and AdV viremia have been identified as risk factors for disseminated disease, a clinically useful cutoff at which treatment should be initiated has not yet been identified. Interpreting a positive AdV PCR remains difficult in the setting of equivocal clinical findings. In a recent retrospective study of pediatric HSCT recipients, AdV was detected in 11 of 26 patients (42%). Seven of these patients were able to clear the virus without intervention. All 5 patients with a viral load \2 Â 10 6 cleared the infection without treatment [24] . In the present study, 4 of the 7 AdV-positive patients had an adenoviral load \2 Â 10 6 , and all 4 of these patients received therapy with efficacy against AdV. Despite this treatment, 1 of the 4 patients with an adenoviral load \2 Â 10 6 died. In another study, the prevalence of disseminated disease was 37%, with a mortality rate of 25% in this subset of patients.
